髓系恶性肿瘤造血干细胞移植后GVHD与GVL的挑战
该视角文章分析髓系恶性肿瘤异基因造血干细胞移植后移植物抗宿主病(GVHD)与移植物抗白血病(GVL)效应在生物学与治疗方面的当前挑战。近十年GVHD机制研究推动新疗法开发,预防改善使非复发死亡率下降,但原发恶性肿瘤复发率未显著改善,GVL生物学认识仍滞后于GVHD。
要点
- GVHD预防与疾病控制改善可能降低了非复发死亡率,但复发率未显著改善。
- GVL效应生物学认识仍滞后于GVHD,调控GVL的治疗手段仍有限。
- 临床试验设计错误是不足之处之一,部分失败可归因于对GVHD病理生理认识不完整。
核心结论
- GVHD预防与疾病控制改善可能降低了非复发死亡率,但原发恶性肿瘤复发率未显著改善。
- 对GVL效应的生物学认识仍滞后于GVHD,调控GVL的治疗手段仍有限。
- 失败原因可归因于对GVHD病理生理认识不完整,或某些情况下临床试验设计错误。
研究设计与样本
- 本文为视角文章,分析GVHD与GVL在生物学和治疗方面的当前挑战,并提供作者个人观点。
主要发现
- 近十年GVHD机制知识重大进展促进了GVHD预防和治疗新疗法的开发。
- GVHD预防与疾病控制改善可能降低了非复发死亡率,但原发恶性肿瘤复发率未显著改善。
- GVL效应生物学认识仍滞后于GVHD,调控GVL的治疗手段仍有限。
- 对血液系统恶性肿瘤生物学认识的提高为新的发展打开了大门,前提是能更好地理解免疫系统与白血病克隆之间的相互作用。
临床怎么用
- 作者认为,从治疗角度看,随机临床试验结果备受关注;从生物学角度看,近期发现尤其是人体研究中的发现备受关注。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although allogeneic hematopoietic stem cell transplantation is a leading treatment approach for myeloid malignancies, challenges in its immune biology and in treatment approaches remain. In the past decade, major advances in the knowledge of mechanisms of graft-versus-host disease (GVHD) has allowed development of new treatments both for GVHD prophylaxis and treatment. However, although successes did occur, failure did as well. Reasons for failure can be linked either to incomplete understanding of the pathophysiology of GVHD, or, in some cases, to errors in the design of clinical trials. Better GVHD prophylaxes and disease control have likely led to decreased nonrelapse mortality (NRM). However, although NRM rates have decreased, rates of relapse of the original malignancy have not significantly improved. Our current understanding of the biology of the graft-versus-leukemia (GVL) effect still lags behind that of GVHD, and treatment approaches to manipulate the GVL effect remain limited. The reasons for such a lag are numerous, but improved knowledge of the biology of hematological malignancies open the gate to new developments, providing that we can better understand the interplay between the immune system with leukemic clones. From a therapeutical perspective, much attention has been paid to the results from randomized clinical trials and from a biological perspective on recent discoveries, especially in the human setting. The objective of this perspective is to analyze what are the current challenges in the biology and treatment of GVHD and GVL and to provide a personal view on how some biological and therapeutic issues could be approached.
引用
- Socie G. Challenges in GVHD and GVL after hematopoietic stem cell transplantation for myeloid malignancies. Blood. 2025. PMID: 40489636. doi:10.1182/blood.2025028617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。